

Supplementary Table 1. Baseline characteristics of the study population stratified by the presence of NAFLD

Characteristic	NAFLD (-) (n=1,459)	NAFLD (+) (n=1,729)	P value
Age, yr	57.6±10.2	55.9±10.0	<0.001 ^a
Male sex	685 (46.9)	912 (52.7)	0.001 ^a
Duration of diabetes, yr	8.4±7.4	6.5±6.1	<0.001 ^a
BMI, kg/m ²	23.0±2.8	25.7±2.9	<0.001 ^a
WC, cm	79.5±7.9	87.1±7.6	<0.001 ^a
SBP, mm Hg	132.8±18.3	136.1±17.0	<0.001 ^a
DBP, mm Hg	90.9±275.7	87.0±11.1	0.587
FPG, mg/dL	158.6±61.5	161.0±55.1	0.246
HbA1c, %	8.3±2.1	8.5±4.5	0.182
KITT, %/min	2.3±1.0	1.9±0.8	<0.001 ^a
Total cholesterol, mg/dL	189.4±37.8	201.5±41.6	<0.001 ^a
Triglyceride, mg/dL	114.9±68.8	174.3±130.8	<0.001 ^a
HDL-C, mg/dL	54.3±14.8	48.7±12.0	<0.001 ^a
LDL-C, mg/dL	112.6±32.6	119.0±37.2	<0.001 ^a
AST, IU/L	25.8±13.0	30.0±17.1	<0.001 ^a
ALT, IU/L	24.7±17.5	35.0±29.7	<0.001 ^a
eGFR, mL/min/1.73 m ²	90.9±15.7	91.5±15.4	0.265
Hs-CRP, mg/dL	0.6 (0.3–1.1)	1.0 (0.5–2.0)	<0.001 ^a
Hypertension	358 (24.5)	527 (30.5)	<0.001 ^a
Insulin	204 (14.0)	144 (8.3)	<0.001 ^a
Metformin	541 (37.1)	841 (48.6)	<0.001 ^a
Sulfonylurea	739 (50.7)	926 (53.6)	0.109
Thiazolidinedione	160 (11.0)	135 (7.8)	0.003 ^a
ARB/ACE inhibitors	60 (4.1)	116 (6.7)	0.002 ^a
Statin	177 (12.1)	328 (19.0)	<0.001 ^a
Incident CKD	220 (15.1)	259 (15.0)	0.977

Values are presented as mean ± standard deviation, number (%), or median (interquartile range).

NAFLD, nonalcoholic fatty liver disease; BMI, body mass index; WC, waist circumference; SBP, systolic blood pressure; DBP, diastolic blood pressure; FPG, fasting plasma glucose; HbA1c, glycosylated hemoglobin; KITT, rate constant for plasma glucose disappearance; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; AST, aspartate aminotransferase; ALT, alanine aminotransferase; eGFR, estimated glomerular filtration rate; Hs-CRP, high-sensitivity C-reactive protein; ARB, angiotensin II receptor blockers; ACE, angiotensin converting enzyme; CKD, chronic kidney disease.

^aStatistically significant.